Sponsor pipeline

Fujifilm Pharmaceuticals U.S.A., Inc. clinical trial pipeline

Get alerts when Fujifilm Pharmaceuticals U.S.A., Inc.'s trials change

3 active trials 0 recruiting 4 disease areas 4 changes in 30 days

Data updated daily from ClinicalTrials.gov, last refresh 2026-09-16

What changed in the last 30 days

2026-09-03
Primary completion pushed: 2025-05-15 → 2026-10
Completion pushed: 2025-12 → 2027-03
NCT03440450 A Phase 1 Dose-escalation Study of FF-10832 for Treatment of Solid Tumors Including… · Phase 1
2026-09-03
Primary completion pushed: 2025-12 → 2026-12
Completion pushed: 2026-07 → 2027-03
NCT04047251 A Study of FF-10850 Topotecan Liposome Injection in Advanced Solid Tumors Including… · Phase 1

Active trials by phase

Phase 1
2
Phase 2
1

Active trials

NCT IDTitleConditionStatusUpdated
Phase 2
NCT05318573 A Study to Evaluate Safety, Efficacy of FF-10832 in Combo With Pembrolizumab in… Advanced Urothelial Carcinoma Active, Not Recruiting 2025-09-04
Phase 1
NCT03440450 A Phase 1 Dose-escalation Study of FF-10832 for Treatment of Solid Tumors Including… Advanced Solid Tumors Active, Not Recruiting 2026-09-02
NCT04047251 A Study of FF-10850 Topotecan Liposome Injection in Advanced Solid Tumors Including… Advanced Solid Tumors Active, Not Recruiting 2026-09-02

Disease areas by active trials

Bladder Cancer (1) · Cholangiocarcinoma (1) · Lung Cancer (1) · Non-Small Cell Lung Cancer (NSCLC) (1)

Get alerts when Fujifilm Pharmaceuticals U.S.A., Inc.'s trials change
Status changes, date slips, and new filings: detected daily, delivered to your inbox.
Start monitoring free